[
  {
    "ts": null,
    "headline": "Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases",
    "summary": "Over the weekend, Bristol Myers Squibb & Co (NYSE:BMY) shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases. Data were presented at the American College of Rheumatology 2024. Also Read: Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue CC-97540 (BMS-986353) is an investigational CD19-targeted CAR T cell t",
    "url": "https://finnhub.io/api/news?id=fc64aee35abcd47f52fe4c13c0745f92c79bc7f138e817db8d298f237457cacb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731954285,
      "headline": "Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases",
      "id": 131465218,
      "image": "https://media.zenfs.com/en/Benzinga/5a6567c00975c0e993a660f916991abc",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Over the weekend, Bristol Myers Squibb & Co (NYSE:BMY) shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases. Data were presented at the American College of Rheumatology 2024. Also Read: Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue CC-97540 (BMS-986353) is an investigational CD19-targeted CAR T cell t",
      "url": "https://finnhub.io/api/news?id=fc64aee35abcd47f52fe4c13c0745f92c79bc7f138e817db8d298f237457cacb"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=eb068adf71bc841cfc69ad76c9a9ab078e4e133ba58cb5ff1f0621466494dfc0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731948120,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 131475993,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=eb068adf71bc841cfc69ad76c9a9ab078e4e133ba58cb5ff1f0621466494dfc0"
    }
  },
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?",
    "summary": "We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion […]",
    "url": "https://finnhub.io/api/news?id=7306241494668f4c28c1717491804c8b6e3c6d2f4d4e8e2404d3341f1de924fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731939588,
      "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?",
      "id": 131448132,
      "image": "https://s.yimg.com/ny/api/res/1.2/ZsrqNB_sdV78LPtS9DZ12A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion […]",
      "url": "https://finnhub.io/api/news?id=7306241494668f4c28c1717491804c8b6e3c6d2f4d4e8e2404d3341f1de924fc"
    }
  },
  {
    "ts": null,
    "headline": "EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer",
    "summary": "The CHMP's opinion is based on the Phase III, open-label CheckMate -8HW trial.",
    "url": "https://finnhub.io/api/news?id=dc7b157fb36eb10992912a7a7ab98c05b3c5a0ca12287cf3668416ba1c502bac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731920991,
      "headline": "EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer",
      "id": 131438836,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/Pharma-1-BMSS-Shutterstock_2320070507.jpg",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The CHMP's opinion is based on the Phase III, open-label CheckMate -8HW trial.",
      "url": "https://finnhub.io/api/news?id=dc7b157fb36eb10992912a7a7ab98c05b3c5a0ca12287cf3668416ba1c502bac"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors",
    "summary": "PRINCETON - Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval for repotrectinib, a...",
    "url": "https://finnhub.io/api/news?id=48436eda40e3767817c75b0beaed724e08b16b7505b06a1fb8b4d9511f39ceef",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731913527,
      "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors",
      "id": 131440001,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "PRINCETON - Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval for repotrectinib, a...",
      "url": "https://finnhub.io/api/news?id=48436eda40e3767817c75b0beaed724e08b16b7505b06a1fb8b4d9511f39ceef"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer",
    "summary": "PRINCETON - Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo plus Yervoy for the...",
    "url": "https://finnhub.io/api/news?id=7277030146a36cd9ffa737a56fa5d304f83d908f9c69fc6c9ba618c1d56f455a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731913451,
      "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer",
      "id": 131439907,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "PRINCETON - Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo plus Yervoy for the...",
      "url": "https://finnhub.io/api/news?id=7277030146a36cd9ffa737a56fa5d304f83d908f9c69fc6c9ba618c1d56f455a"
    }
  }
]